The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine

被引:45
作者
Davis, MP [1 ]
Homsi, J [1 ]
机构
[1] Cleveland Clin Fdn, Harry R Horvitz Ctr Palliat Med, Cleveland, OH 44195 USA
关键词
CYP2D6; palliative medicine; drug metabolism; drug interactions; ethnic differences; pharmacokinetics;
D O I
10.1007/s005200000222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The enzymes in the cytochrome p450 monooxygenase system (CYP) are the major enzymes responsible for metabolizing medications. The CYP2D6 isomer is responsible for metabolizing certain opioids, neuroleptics, antidepressants and cardiac medications. Owing to CYP2D6's low capacity and high affinity it is easily saturated by substrate and/or inhibited, resulting in pharmacokinetic interactions. Polymorphisms of the structural gene are common, leading to wide inter-individual and ethnic differences in drug metabolism. Clinically important drug interactions, which may be anticipated in the palliative medicine population, are reviewed.
引用
收藏
页码:442 / 451
页数:10
相关论文
共 105 条
[1]  
ACHAMALLAH NS, 1992, AM J PSYCHIAT, V149, P1406
[2]   CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline [J].
Alfaro, CL ;
Lam, YWF ;
Simpson, J ;
Ereshefsky, L .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (02) :155-163
[3]   Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing [J].
Ammon, S ;
Hofmann, U ;
Griese, EU ;
Gugeler, N ;
Mikus, G .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (03) :317-322
[4]   Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4 [J].
Ball, SE ;
Scatina, JA ;
Kao, J ;
Ferron, GM ;
Fruncillo, R ;
Mayer, P ;
Weinryb, I ;
Guida, M ;
Hopkins, PJ ;
Warner, N ;
Hall, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (03) :288-294
[5]  
Banning A M, 1999, Ugeskr Laeger, V161, P6500
[6]   Drug interactions in palliative care [J].
Bernard, SA ;
Bruera, E .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) :1780-1799
[7]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[8]   Clonazepam and sertraline: Absence of drug interaction in a multiple-dose study [J].
Bonate, PL ;
Kroboth, PD ;
Smith, RB ;
Suarez, E ;
Oo, C .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (01) :19-27
[9]  
Bradford LD, 1998, PSYCHOPHARMACOL BULL, V34, P797
[10]  
CAI W, 2000, CHUNG HUA I HSUEH TA, V17, P181